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The immune response after brain injury is highly complex and involves both local and
systemic events at the cellular and molecular level. It is associated to a dramatic
over-activation of enzyme systems, the expression of proinflammatory genes and the
activation/recruitment of immune cells. The complement system represents a powerful
component of the innate immunity and is highly involved in the inflammatory response.
Complement components are synthesized predominantly by the liver and circulate in
the bloodstream primed for activation. Moreover, brain cells can produce complement
proteins and receptors. After acute brain injury, the rapid and uncontrolled activation of
the complement leads to massive release of inflammatory anaphylatoxins, recruitment of
cells to the injury site, phagocytosis and induction of blood brain barrier (BBB) damage.
Brain endothelial cells are particularly susceptible to complement-mediated effects, since
they are exposed to both circulating and locally synthesized complement proteins.
Conversely, during neurodegenerative disorders, complement factors play distinct roles
depending on the stage and degree of neuropathology. In addition to the deleterious
role of the complement, increasing evidence suggest that it may also play a role in
normal nervous system development (wiring the brain) and adulthood (either maintaining
brain homeostasis or supporting regeneration after brain injury). This article represents a
compendium of the current knowledge on the complement role in the brain, prompting
a novel view that complement activation can result in either protective or detrimental
effects in brain conditions that depend exquisitely on the nature, the timing and the degree
of the stimuli that induce its activation. A deeper understanding of the acute, subacute
and chronic consequences of complement activation is needed and may lead to new
therapeutic strategies, including the ability of targeting selective step in the complement
cascade.
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THE COMPLEMENT SYSTEM: A BACKGROUND
In 1891, Buchner et al. discovered and reported a heat labile
factor able to kill bacteria in blood, naming it “alexin” (in Greek,
means “to ward off ”) (Ehrlich and Morgenroth, 1899; Buchner,
1981; Nesargikar et al., 2012). Bordet subsequently demonstrated
that immune lysis requires the presence of two factors: a heat-
labile lytic factor similar to “alexin” and a heat-stable factor,
which he termed “sensitizer” (now known to be the antibody)
(Morgan, 1990; Nesargikar et al., 2012). In 1899, Paul Ehrlich
refined this theory describing the requirement for a supplemen-
tary molecule, named “the complement” (which replaced the
historical term “alexin”) necessary to induce antibody-induced
artery occlusion; TP, terminal pathway; VCAM-1, vascular cell adhesion
protein-1; WT, wild type.
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bacterial lysis. Over one hundred years later, the role of the
complement system is known to extend well-beyond that of
a supplementary molecule. This physiological system is now
recognized as an extremely potent component of the defense
cascade of innate immunity, able not only to scavenge pathogens
and antigens but also to respond to endogenous so called dan-
ger signals. Numerous experimental and clinical studies have
recently demonstrated the involvement of this system in differ-
ent acute and chronic pathological conditions, highlighting the
importance of complement as a crucial factor in the activation
and control of the generalized immune response. In addition,
beyond elimination of potentially toxic molecules, its contribu-
tion to diverse homeostatic processes, such as lipid metabolism,
angiogenesis, tissue modeling and maintenance has been recently
proposed.
The complement system consists of more than 30 fluid-
phase and cell-associated proteins (Wagner and Frank, 2010),
each with different functions including, but not limited to, ini-
tiator molecules, substrates, regulators, inhibitors and receptors
for complement proteins. The activation of the complement
system can be triggered by exogenous and/or endogenous dan-
ger signals (pathogen-associated molecular patterns—PAMPs
and/or damage-associated molecular patterns—DAMPs respec-
tively) through the classical (CP), lectin (LP) or alternative
pathway (AP). These pathways are each activated by different
types of danger signals but share the same cascade-like activation
system consisting of a number of proteolytic reactions, during
which an inactivated protein is cleaved into smaller and active
peptide fragments (see Figure 1). Briefly, the CP is activated
through the binding of C1q to antigen-antibody complexes or
directly by specific molecules including β-amyloid, C reactive
protein (CRP), DNA and/or apoptotic bodies. The LP is activated
through different pattern recognition receptors, including, in
humans, mannose binding lectin (MBL), ficolin-1, ficolin-2 and
ficolin-3 and collectin-11 (CL-11). These lectin molecules bind to
high-density arrays of mannose, fucose and N-acetylated sugars
exposed by pathogens or by altered host cells. The activation of
the AP is driven by the spontaneous hydrolysis of circulating
C3 (tick-over process) into C3(H2O) on cellular surfaces. In
addition, another complement activation pathway, named the
extrinsic pathway, that is driven by serine protease components
of the coagulation system, has been described (Huber-Lang et al.,
2006). Increasing evidence suggests an intimate but not yet fully
disclosed interaction between the complement and coagulation
cascades which is particularly relevant in cerebrovascular disease,
in which the balance between coagulation and fibrinolysis may be
clinically manipulated for therapeutic purposes. All these path-
ways, converging on the C5 convertase formation (see Figure 1),
activate a common cascade (named the terminal pathway, TP)
through the cleavage of C5 into C5a and C5b. The former, along
with C3a (generated by up-stream cleavage of C3), functions as
anaphylatoxins, inducing a potent inflammatory response and
stimulating the recruitment of peripheral immune cells. The latter
fragment (C5b) binds to the targeted cell, allowing the assembly
of C6, C7, C8 and C9 into a pore called membrane attack complex
(C5b-9 or MAC), that causes the direct cellular lysis. Another crit-
ical consequence of complement activation is that many of these
cleavage products, such as C3b and C4b as well as C5b, work as
opsonins to trigger an overactivation of the phagocytic response.
In addition, complement components are able to orchestrate an
immune reaction by communicating with multiple immune cells
through different receptors, thereby leading to robust local and
systemic inflammatory responses (Ricklin and Lambris, 2007).
The complement system is also endowed with highly sophis-
ticated regulatory mechanisms that serve to finely tune its physi-
ological function (Ricklin and Lambris, 2007). The complement
regulatory molecules are classified as fluid-phase or membrane-
bound regulators (Table 1). One of the most well-studied cir-
culating complement regulators is C1 inhibitor (C1-INH), a
serine-protease that acts to inactivate the C1q/C1r/C1s and
the MBL/MASP-1/MASP-2 complex. At high concentrations,
C1-INH may also inactivate C3b generated by the AP (Wagner
and Frank, 2010) as well as molecules associated with the kinin,
fibrinolytic and coagulation systems (e.g., factor XII and IX)
(Ehrnthaller et al., 2011).
The complement system also comprises a wide array of specific
receptors for complement proteins by which the system induces
phagocytosis and triggers the inflammatory response via direct
communication with immune cells (Ricklin et al., 2010). The
most important complement receptors include: (1) C1q receptors
(gC1qR, C1qRp and cC1qR) that have been associated with the
phagocytic process; (2) the integrin receptors, including com-
plement receptor 3 (CR3, also known as CD11b/CD18) and 4
(CR4, also known as CD11c-CD18) that bind to iC3b fragment
(a complement product coming from a further cleavage of C3b)
to further promote cellular phagocytosis, cytokine responses,
leukocyte trafficking and synapse formation; (3) C3a (C3aR) and
C5a (C5aR or CD88) receptors that trigger a sustained proinflam-
matory signaling. Overall the role of the complement receptors is
still to be fully elucidated.
SOURCES AND COMPARTMENTS OF ACTIVATION
SOURCES IN HEALTH AND BRAIN INJURY
Complement proteins account for approximately 4% of total
blood proteins. Physiologically, they monitor the blood and the
cell surfaces and are constantly primed for activation when poten-
tial threats are detected. The liver represents the major source of
complement components released into the systemic circulation,
and hepatocytes are known to be capable of synthesizing the myr-
iad classes of complement proteins (Morgan and Gasque, 1997;
Brennan et al., 2012). Other cell types, such as fibroblasts, mono-
cytes, epithelial and endothelial cells and, most notably, all brain
cell populations, are programmed to produce selected comple-
ment factors. The adult brain, once considered immunologically
privileged, is subjected to considerable immune surveillance and
possesses its own immune competence. Current evidence suggests
that astrocytes, neurons, microglia and oligodendrocytes are all
able to directly synthesize several factors, regulators and receptors
for complement proteins (Woodruff et al., 2010; Veerhuis et al.,
2011). Neurons, astrocytes and microglia can produce comple-
ment initiators such as C1q (Stevens et al., 2007) and C3, receptors
such as C3aR and C5aR as well as inhibitors such as C1-INH and
CD59, although other complement proteins can be specifically
produced by the different brain cells. Under normal conditions,
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FIGURE 1 | The complement system: an overview. Classical
pathway (CP): C1q, the CP initiator, recognizes and binds
antigen-antibody complexes or specific molecules, including
β-amyloid, C reactive protein (CRP), DNA and apoptotic bodies. After
binding, the C1r and C1s proteases subsequently cleave C4 and C2
to generate C4a, C4b, C2a, C2b, permitting the formation of C4b2a
(CP C3 convertase). This complex cleaves C3 into C3a, which, in turn,
acts as potent anaphylatoxin, and C3b that binds to the complex
forming the C4b2a3b protein block (CP C5 convertase). Lectin
pathway (LP): MBL, ficolin-1, ficolin-2, ficolin-3 and collectin-11, the
LP initiators, recognize and bind high-density arrays of mannose,
fucose and N-acetylated sugars exposed by pathogens or by
self-altered cells. After binding, the MBL-associated serine proteases
(MASPs), MASP-1 and -2, associated in complex with the above
recognition molecules (MBL/ficolins), cleave C4 and C2, thereby
forming C3 convertase and C5 convertase in a similar manner to that
of the CP (Ehrnthaller et al., 2011). The role of the third serine
protease, called MASP-3, remains unclear (Kjaer et al., 2013).
Alternative pathway (AP): the activation of the AP is driven by a
spontaneous hydrolysis of circulating C3 (called tick-over process) to
form C3(H2O). This molecule then associates factor B and factor D to
form C3bBb (AP C3 convertase). Similar to the C3 convertase
generated in the CP and LP, this complex splits C3 into C3a and C3b,
with the latter creating a new C3 convertase (AP amplification loop,
dotted line), and/or binding C3 convertase already present to create
the C3bBb3b complex (AP C5 convertase). Extrinsic pathway: the
recent characterization of this activation pathway suggests that it is
driven by activated proteolytic enzymes, including thrombin, plasmin,
kallikrein, factor XIIa. Thrombin possesses its own C5 convertase
activity and, under undefined conditions, has been shown to have the
capacity to directly cleave C5 to generate the correspondent active
fragments (Huber-Lang et al., 2006). Recently, it has been shown that
the coagulation serine proteases are likewise able to cleave C3
(Markiewski et al., 2007; Amara et al., 2010). Terminal pathway: CP,
AP, LP and the extrinsic pathway all converge at C5 convertase
formation, activating a common cascade through the cleavage of C5
into the anaphylatoxin C5a and the active C5b. Finally, (1) C3b
fragment binds the targeted cell allowing the assembly of C6, C7, C8
and C9 in a pore called membrane attack complex (C5b-9 or MAC),
that causes the direct lysis of the cell; (2) many fragments, such as
C3b and C4b as well as C5b, work as opsonins triggering an
overactivation of the phagocytic response; (3) altogether complement
components are able to orchestrate an adaptative immune reaction
by communicating with multiple immune cells (Ricklin and Lambris,
2007) through different receptors, leading to a robust local and
systemic inflammatory response.
complement synthesis in brain cells is low and is believed to
be involved in physiological processes during brain develop-
ment and homeostasis (vide infra). Following cellular injury
and damage, complement synthesis in brain cells can markedly
increase and contribute to tissue damage (Woodruff et al., 2010).
The activation of the complement system has been extensively
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Table 1 | Main complement regulators.
Regulator Abbreviation Target pathway Functions
Fluid phase regulators:
C1-inhibitor C1-INH CP and LP Inhibits C1r, C1s, MASP-1 and MASP-2 proteolytic activities
MBL/ficolin-associated protein 1 MAP-1 LP Binds MBL and ficolins and inhibits C4 deposition
Factor I FI CP, LP and AP Cleaves C3b and C4b in their inactive fragments
C4 binding protein C4BP CP and LP Accelerates decay of classical and lectin C3 convertase along
with FI
Factor H FH AP Accelerates decay of alternative C3 convertase along with FI
Carboxypeptidase N CP, LP and AP Inactivates C3a and C5a anaphylatoxin
Membrane-bound regulators:
CR1 CP, LP and AP Binds C3b,C4b and C1q to promote phagocytosis of immune-
complexes and accelerates decay of convertases
CD46 CP, LP and AP Binds C3b and C4b accelerating decay of C3 convertase,
cofactor for FI
CD55 CP, LP and AP Accelerates decay of C3 convertases
Complement receptor 1-related protein y Crry CP, LP and AP Cleaves C3b and C4b inhibiting C3 convertases formation,
cofactor for FI
CD59 CP, LP and AP Binds C8 and C9 preventing the assembly of C5b-9 lytic
complex
CP, classical pathway; LP, lectin pathway; AP, alternative pathway.
demonstrated in both chronic neurodegenerative and acute neu-
roinflammatory central nervous system (CNS) conditions, with
neurons showing selective vulnerability to complement medi-
ated damage (Singhrao et al., 2000), most likely due to their
low basal expression of cell-membrane associated complement
regulators (e.g., CD55 and CD46). However, distinctive kinetics
of complement activation between chronic neurodegeneration
and acute brain injury and neuroinflammatory insults occur. In
neurodegenerative disorders, local complement biosynthesis and
uncontrolled complement activation in the tissue are crucial for
contributing to neuronal loss and local inflammation, with blood
brain barrier (BBB) injury appearing during the disease chronic
stages (Gasque et al., 2000). Conversely, one common feature of
acute brain injuries, such as stroke, subarachnoid hemorrhage
and brain trauma, includes early and severe BBB breakdown.
Thus, in addition to complement proteins and regulators pro-
duced locally in the tissue, brain parenchyma immediately follow-
ing acute injury is rapidly invaded by a number of inflammatory
cells and molecules, including complement proteins circulating in
high concentration in blood (Brennan et al., 2012). Although this
process is essential for triggering the removal of cellular debris,
when over-activated, it may severely affect neuronal and glial
integrity in cells spared at the time of the primary injury.
THE BRAIN ENDOTHELIUM: A CRITICAL COMPARTMENT OF ACTION
Brain vascular endothelial cells are major players in this cas-
cade of events. They represent the physical barrier between
the periphery and the brain parenchyma and since they are
continuously exposed to blood-derived complement effectors,
they remain a target of circulating active complement molecules
(Bossi et al., 2011). In response to stress signals, endothelial cells
may expose DAMPs to become selective targets for complement
initiators. Endothelial cells can also produce selected comple-
ment components, subsequently increasing the local availability
and cell toxicity of these molecules. The complement-mediated
endothelial damage promotes BBB leakage with a subsequent
influx of active complement fragments and cytokines, as well as
immune cells into the injured brain tissue with amplification of
local inflammation (Figure 2). Endothelial cells may therefore
play a central role in triggering/modulating local complement
activation and in the partition of complement components from
blood to brain.
C1q is known to directly bind endothelial cells (Yin et al.,
2007; Bossi et al., 2008) inducing the expression of adhesion
molecules, such as E-selectin, intercellular adhesion molecule-
1 (ICAM-1) and vascular cell adhesion protein-1 (VCAM-1;
Lozada et al., 1995), and the release of chemokines and cytokines,
such as IL-8, monocyte chemotactic protein-1 (MCP-1) and IL-
6 (van den Berg et al., 1998). It has been reported that C1q
and MBL compete for the binding to endothelial surfaces (Oros-
zlán et al., 2007). MBL deposition on endothelial cells has been
demonstrated independently from C1q, both in in vitro and in
vivo settings and is known to occur after oxidative stress on
human umbilical vein endothelial cells (HUVECs), accompanied
with iC3b deposition. Furthermore, MBL and iC3b deposition
are reduced in the presence of functionally inhibitor anti-MBL
antibodies (Collard et al., 2000) suggesting that MBL adhe-
sion on endothelial cells mediates complement activation. It has
also been proposed that MBL deposition is driven by increased
endothelial expression of cytokeratin 1 after hypoxia, since anti-
cytokeratin treatment is able to attenuate MBL and iC3b pres-
ence on HUVECs under the same conditions (Collard et al.,
2001). Although the specific MBL-binding molecules expressed
by damaged endothelial cells remain unclear, MBL deposition
has been demonstrated in vivo in different organs, such as heart
(Pavlov et al., 2012), kidney (Møller-Kristensen et al., 2005;
Castellano et al., 2010), intestine (McMullen et al., 2006) and
brain (Gesuete et al., 2009; Orsini et al., 2012) following ischemia
reperfusion injury. MBL deposition also occurs after both human
and experimental traumatic brain injury (TBI; Longhi et al.,
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FIGURE 2 | Complement-mediated endothelial damage: working
hypothesis. Healthy brain endothelial cells physically isolate the brain
parenchyma from the blood compartment. Under physiological conditions,
complement proteins, such as C1q, LP initiators, C3 and C5, monitor the
blood and the cell surfaces for potential threats (A). The additional
complement factors that normally circulate in the bloodstream, have been
omitted in this figure for purposes of clarity and simplification. When a
cerebrovascular injury occurs (B), endothelial cells may change their
glycosylation profile, leading to the exposure of high density arrays of
sugar (DAMPs). LP initiators, through their carbohydrate recognition
domains, can recognize and bind altered endothelial cells, leading to LP
complement activation (B). Complement activated fragments trigger the
expression of adhesion molecules and the release of chemokines and
cytokines (not shown) on endothelial cells, resulting in the worsening of
the BBB leakage (B→C). The injured brain parenchyma is then rapidly
invaded by the full immune arsenal, including the complement proteins,
cytokines and immune cells (e.g., monocytes) belonging to the blood
compartment, leading to amplification of local damage (C). The
overactivation of the complement system in brain tissue leads to: (1) a
potent inflammatory response and the recruitment of peripheral immune
cells mediated by C3a and C5a anaphylatoxins, (2) direct lysis of neurons
and other brain cells, including those that are potentially savable, by
C5b-9, (3) opsonization with subsequent microglia/macrophage
phagocytosis of the target cells by C3b and C5b. This schema proposes a
key role for endothelial cells in triggering local LP complement activation
and suggests that targeting the peripheral compartment may represent
effective strategy for brain protection from injury and different acute CNS
diseases.
2014), suggesting that this response represents one of several
toxic events after trauma (Figure 2). Another protein belong-
ing to the LP, the serine protease MASP-1, is currently under
evaluation for its effect on endothelium. It has been demon-
strated that MASP-1 induces p38- mitogen-activated protein
kinases (MAPK) activation, NFkappaB signaling and Ca2+ mobi-
lization in HUVECs, inducing IL-6 and IL-8 production (Jani
et al., 2014) as well as E-selectin expression (Dobó et al., 2014).
MASP-1, like thrombin, also activates endothelial cells directly by
cleaving the protease activated receptors (PARs; Megyeri et al.,
2009). Other complement components have been demonstrated
to interact with endothelial cells and promote vascular toxicity.
For example, anaphylotoxin C3a and C5a may interact with the
corresponding receptors on endothelial cells (Van Beek et al.,
2000) inducing cytoskeletal modifications (Schraufstatter et al.,
2002; Bossi et al., 2011) and increasing mRNA levels of IL-
8, IL-1β and RANTES (regulated on activation normal T cell
expressed and secreted) (Monsinjon et al., 2003). In addition,
C3 knock-out (C3-/-) mice showed reduced immune complex-
mediated vascular leakage when compared to wild type (WT)
mice (Lister et al., 2007; Bossi et al., 2011), even though a direct
toxic effect of C3a on endothelial cells has not been demon-
strated (Schraufstatter et al., 2002). The same authors reported
that C5a induces endothelial cells shrinkage with subsequent
increased vascular permeability. The vascular properties of C5a
have also been reported in an endotoxin-induced permeability
model, in which C5aR-siRNA was able to limit the vascular
leakage (Liu et al., 2010). In addition to the effects on the
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aforementioned complement components, TP proteins can lead
to vascular dysfunction. For example, the circulating soluble
C5b-9 (sC5b-9), a cytotoxic inactive complex formed by C5b-9
terminal lytic complex associated with soluble regulators, induced
vascular leakage on HUVECs and in an in vivo model of mesen-
teric microvessel permeability (Tedesco et al., 1997; Bossi et al.,
2004).
Taken together, these data suggest that protein products
derived from complement activation can act on endothelial
cells and shift, via different mechanisms, endothelial activation
towards a toxic phenotype with associated increased vascular
permeability.
THE DISRUPTIVE OVERWHELMING POWER OF
COMPLEMENT IN ACUTE NEUROINFLAMMATORY BRAIN
CONDITIONS
Stroke and TBI represent two major types of acute neuroin-
flammatory brain conditions. Stroke remains the third leading
cause of death worldwide and the first cause of long-term dis-
ability in Europe (Corbyn, 2014), while TBI remains the prin-
cipal cause of death and disability in active young adults today
(Lingsma et al., 2010). Moreover, TBI has been proposed to
be an independent risk factor for stroke (Burke et al., 2013).
Fewer than 10% of stroke patients are eligible for treatment
with tissue-type plasminogen activator, the only current therapy
available, to date. Despite the creation of increasingly widespread
networks of organized acute stroke units, a high proportion of
hospitalized stroke patients survive with permanent neurological
impairment and disability. Similarly, no treatment is currently
available for TBI and surviving patients often report severe and/or
prolonged disabilities. Although stroke and TBI share impor-
tant molecular and cellular pathogenic mechanisms leading to
the progression of damage, due to the different nature of the
primary insult, they are also associated with specific cellular
vulnerability and activation of distinct pathogenic cascades. We
will focus on these two conditions that induce profound alter-
ations of both central and peripheral immune system (Bellavance
and Rivest, 2012; Chamorro et al., 2012), review the available
data on the disruptive overwhelming power of complement in
acute brain injury and summarize both the common and diver-
gent relevant cellular and molecular mediators which represent
candidates for the development of novel targeted therapeutic
strategies.
STROKE
Evidence of complement system activation
A role for the complement system in ischemia/reperfusion injury
was first suggested by Hill and Ward (1971), who demonstrated
the presence of C3-cleavage factors with chemotactic activity in
damaged rat myocardial tissue. Activation of the complement
system after ischemia/reperfusion injury in different organs such
as heart, kidney, intestine and brain has been subsequently docu-
mented (Arumugam et al., 2009; Cervera et al., 2010; Orsini et al.,
2012), suggesting that complement represents a common but key
mechanism involved in the exacerbation of tissue damage after
ischemia.
In stroke patients, activation of the complement system has
been documented in plasma or serum samples as well as in
post-mortem brain tissues. Specifically, C3a and C5a plasma
levels were shown to increase post-stroke, reaching peak values
at days 1 and 14 respectively (Mocco et al., 2006b). Follow-
up studies have extended these observations, documenting an
increase in C3 and C3a plasma levels in patients with small
vessel disease or cardioembolic stroke when compared to controls,
and additionally demonstrating a positive correlation between
their levels and unfavorable outcome in cardioembolic stroke
(Stokowska et al., 2013). Acute (day 1–2) plasma sC5b-9 levels
in patients with either ischemic or hemorrhagic stroke have been
shown to be significantly increased when compared to non-stroke
controls (Széplaki et al., 2009; Zanier et al., 2014) and shown to
increase over time during post-stroke recovery (Pedersen et al.,
2004). In a cohort of mild stroke patients, Mocco et al. (2006b),
observed decreased plasma sC5b-9 levels when compared to
non-stroke controls. These data highlight that interpretation of
alterations in systemic concentrations of complement factors is
not straightforward, since injury severity or timing issues may
markedly affect plasma dynamics of complement activation prod-
ucts. Furthermore, caution must be observed when interpreting
the clinical data, since both an increase and decrease of circulating
complement factors may be regarded as indicator of complement
activation reflecting either increased synthesis or increased con-
sumption/deposition.
In addition to the analysis of circulating factors, the presence
of differing complement proteins in post-mortem brain tissues
of human stroke patients has also been investigated, provid-
ing important information regarding the specific cell popula-
tion associated with the expression or deposition of selective
factors. Immunohistochemical analysis of human brain tissue
has revealed that expression of factors, such as C1q, C4d, C3c
and C9, is detectable in neurons in ischemic brain regions but
absent in non-stroke control tissues (Pedersen et al., 2009).
C1q immunostaining was associated with microglial cells, while
C3c and C9 staining were associated both with microglia and
astrocytes in necrotic areas. Existing data concerning C5b-9
complex is more controversial, with some authors finding no
deposition of this factor in ischemic brain tissue (Pedersen
et al., 2009), while others reporting increased C5b-9 and C3d
immunoreactivity in infarcted areas (Lindsberg et al., 1996).
Additionally, immunopositivity for the regulators CD59 and
CD55 (Table 1) which is present in healthy controls, is unde-
tectable in ischemic brains (Pedersen et al., 2009), suggesting that
down-regulation of these molecules may contribute to ischemic
pathology.
Additional information concerning the role of key comple-
ment mediators in brain ischemia comes from experimental
animal studies. The earliest studies were performed using cobra
venom factor (CVF) that induces non-selective but total com-
plement depletion. Rats treated with CVF 1 day before transient
middle cerebral artery occlusion (tMCAo), showed higher reac-
tive hyperaemia and better preservation of somatosensory evoked
potentials when compared to vehicle-treated rats (Vasthare et al.,
1998). A subsequent study demonstrated reduced cerebral infarct
volume and atrophy in adult and neonatal rats following CVF
Frontiers in Cellular Neuroscience www.frontiersin.org November 2014 | Volume 8 | Article 380 | 6
Orsini et al. Versatility of the complement system in the brain
administration (Figueroa et al., 2005). In contrast, other studies
testing the efficacy of prophylactic CVF administration failed to
show any protective effect in a thromboembolic stroke model
in rabbits (Lew et al., 1999) or in an hypoxia/ischemia model
in immature rats (Lassiter et al., 2001). The species selection
and the differences in stroke models may explain, in part,
these discordant observations. However, these data also suggest
that full complement depletion may not be an optimal ther-
apeutic strategy and that more targeted manipulation aimed
at inhibiting/deleting selective complement components should
be evaluated. To this end, studies concerning the inhibition of
downstream-cascade complement proteins have been conducted
to elucidate their specific contribution in mediating brain dam-
age after ischemia. C3-/- ischemic mice showed better neuro-
logical scores, reduced ischemic volume, granulocyte infiltration
and oxidative stress when compared to WT mice subjected to
cerebral ischemia, confirming the deleterious effects of com-
plement system activation in this condition (Atkinson et al.,
2006; Mocco et al., 2006a). Furthermore, the expression of C3aR
has been shown to increase after cerebral ischemia (Barnum
et al., 2002) and its pharmacological inhibition with a C3aR
antagonist conferred protection of anatomical damage associ-
ated with reduced endothelial ICAM-1 staining (Ducruet et al.,
2008).
The precise role of C5 in brain ischemic injury remains
unclear. Recent in vitro data has shown that brain ischemia,
mimicked by oxygen-glucose deprivation, induces the cleav-
age of the C5 expressed by neurons leading to apoptotic cell
death signaling (Pavlovski et al., 2012). In vivo studies have
shown disparate results depending on post-stroke evaluation
time points. Twenty-four hours after ischemic onset, Mocco
et al. found no effect on neurological scores or ischemic volume
in C5 knock-out mice (C5-/-) when compared to WT mice
(Mocco et al., 2006a). Conversely, Arumugam et al. reported
improved functional outcome with reduced brain damage in
C5-/- compared with their WT littermates, when assessed 72 h
after injury (Arumugam et al., 2007). Brain expression of C5aR
increases in mice after cerebral ischemia (Barnum et al., 2002)
and although the administration of C5aR antagonist elicited
only a slight improvement in neurological deficits and infarct
volume in 60 min tMCAo mice (Arumugam et al., 2007),
more clear cut protective effects on neurological deficits and
infarct volume were observed after 45 min tMCAo (Kim et al.,
2008).
The deleterious role of terminal complement pathway
activation has been assessed in experimental stroke models
using a variety of strategies. The first was to investigate the
susceptibility of C6 knock-out mice (C6-/-) to ischemic brain
damage. No differences concerning either neurological deficits
or ischemic damage were observed in C6-/- compared to WT
mice (Elvington et al., 2012). The second strategy was aimed at
studying the susceptibility to ischemia in CD59 knock-out mice
(CD59-/-), which lack this important endogenous membrane-
bound inhibitor of C5b-9 formation (see Table 1). Three days
after 30 min tMCAo, CD59-/- showed increased infarct volume,
greater neurological deficits and increased brain swelling com-
pared to injured WT mice, indicating that CD59 may exert a
protective role by inhibiting the C5b-9 assembly on damaged
target cells. In contrast, there were no differences on those
outcomes between the two strains when the mice were sub-
jected to 60 min tMCAo followed by 2 days of reperfusion,
despite the increase in the number of terminal-dUTP-nick end
labeled (TUNEL)-positive cells in CD59-/- compared to WT
(Harhausen et al., 2010). In addition, the differences observed
were restricted to male mice, while no effects were found in
female mice (Harhausen et al., 2010). The most recent strategy
has been to investigate the role of CD55 regulator (see Table 1)
after ischemic brain insults. Primary cortical rat neurons were
exposed to hypoxia-like conditions, mimicked by NaCN expo-
sure, and incubated with or without the complement inhibitor
CD55. The complement inhibitor prevented dendritic spine loss
induced by hypoxia and increased cell viability following the
hypoxic insult. In addition, CD55 treatment attenuated the
increase of C3 and C3aR neuronal expression, as well as the
generation of C3a and C5b-9 triggered by hypoxemia (Mack
et al., 2006; Wang et al., 2010). Taken together, these different
strategies combine to suggest an involvement of the terminal
complement pathway activation in inducing cerebral damage after
ischemia.
Distinct roles of activation pathways
Further research has been performed on the initiators of the
complement cascade to better clarify the specific contribution
of the different activation stimuli. It has been demonstrated
that C1q, the initiator of the CP, is present on neuronal cell
bodies and in cellular debris beginning 6 h after tMCAo (Mack
et al., 2006). Furthermore, widespread C1q biosynthesis has been
detected in rat microglia, but not in astrocytes or neurons,
24 h after global cerebral ischemia (Schäfer et al., 2000). Nev-
ertheless, we and others have demonstrated that C1q knock-
out (C1q-/-) mice were not protected against brain ischemia
(De Simoni et al., 2003; Mocco et al., 2006a), suggesting that
this component of the complement cascade does not directly
induce post-ischemic neuronal damage. Conversely, neonatal
C1q-/- mice subjected to hypoxic/ischemic brain injury showed a
reduction of infarct volume, neurological deficits, C3 deposition
and granulocytes infiltration in infracted areas compared to WT
mice (Ten et al., 2005). The apparent discrepancy regarding
the C1q role after adult vs. neonatal ischemic injury might be
explained by differing age-dependent complement susceptibil-
ity. Indeed, it has been demonstrated that a developmentally-
related increase in C1q, FB, C3, C4 and C5 expression occurs
up to 24 months in mice (Reichwald et al., 2009; Stephan
et al., 2013). Although no data are available regarding the
expression of C1q, C1q receptors or complement regulators in
newborn mice, it is known that C1q is extremely important
during neuronal wiring and synapse elimination (vide infra
and see Stephan et al., 2012), suggesting a higher suscepti-
bility/sensitivity to C1q-mediated effects in newborn vs. adult
neurons.
C1-INH, with its ability to bind and inactivate C1r and C1s,
has been suggested to be one of the major regulators of the CP
(Ziccardi, 1981). However, subsequent studies (Davis et al., 2010)
have demonstrated that this molecule is able to inhibit both the
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classical and the LPs. Furthermore, it has been shown that C1-
INH possesses a greater ability to inactivate MASP-2 than classical
proteases, suggesting that the LP might be a more relevant target
for C1-INH compared to the CP (Kerr et al., 2008). Additional
studies have shown that exogenous administration of C1-INH
was protective in a variety of brain ischemia experimental models
(Heimann et al., 1999; Akita et al., 2003; De Simoni et al., 2003,
2004; Storini et al., 2005; Gesuete et al., 2009; Heydenreich et al.,
2012). We have reported that mice subjected to cerebral ischemia
and treated with C1-INH showed reduced ischemic volume,
neurological deficits, degenerating cells and leukocytes infiltration
in the damaged parenchyma when compared to saline-treated
ischemic mice (De Simoni et al., 2004). The protective effects
elicited by C1-INH administration were associated with reduced
mRNA expression of endothelial adhesion molecules, including
P-selectin and ICAM-1, normally induced by ischemic injury
(Storini et al., 2005). More recently, Heydenreich et al. reported
that C1-INH administration resulted in a significant reduction of
BBB leakage compared to saline in ischemic mice (Heydenreich
et al., 2012). In order to better understand the molecular targets
of C1-INH, we analyzed the effect of C1-INH administration
in C1q-/- mice subjected to cerebral ischemia. Although adult
C1q-/- mice were not protected from ischemic injury, C1-INH
was effective in reducing the ischemic volume in C1q deprived
mice, suggesting that C1-INH protective effects are not medi-
ated by the CP. Taken together, this recent evidence supports
the hypothesis for a central role of LP in C1-INH mediated
protection, since: (1) C1-INH binds MBL with high affinity in
vitro, (2) C1-INH and MBL co-localize on ischemic endothelium
in vivo; and (3) C1-INH administration reduces the levels of
functional MBL/MASP-2 complexes in the plasma of ischemic
mice (Gesuete et al., 2009).
Detailed analysis of the MBL gene in humans reveals that
a surprisingly high percentage of individuals (15–30% of the
Caucasian population) carry MBL polymorphisms leading to
low circulating MBL levels. Notably, in 2 independent studies,
MBL deficiency has been associated with favorable outcome in
stroke patients (Cervera et al., 2010; Osthoff et al., 2011) pro-
viding an additional rationale for the development of further
studies to better understand the specific pathogenic role of MBL
and of the other LP activators in stroke. In mice subjected to
cerebral ischemia, MBL deficiency was associated with reduced
neurological deficits, brain lesion and C3 deposition compared
to WT mice during the acute post-injury phase (Cervera et al.,
2010; Orsini et al., 2012). However, 7 days after the insult, MBL
knockout mice (MBL-/-) did not show any evidence of neuronal
protection, indicating that MBL may be necessary during tissue
repair processes (Ducruet et al., 2011), suggesting that transient
MBL inhibition may be a desirable and efficacious therapeutic
strategy. Recently, we have demonstrated that pharmacological
inhibition of MBL is highly protective in models of cerebral
ischemia, possessing a wide window of efficacy both in mice
and rats. We have reported that: (1) treatment with Polyman2,
a dendrimeric molecule binding MBL with high affinity, induced
a reduction of neurological deficits and ischemic volume when
administered up to 24 h after induction of injury in mice; and
(2) a functional inhibitory neutralizing antibody against MBL
induced a long-lasting (up to 1 month) reduction of neurolog-
ical deficits and ischemic volume when administered 18 h after
ischemia in rats (Orsini et al., 2012). In addition, we have demon-
strated that MBL was deposited specifically along the luminal
side of ischemic vessels, up to 48 h post-injury. We hypothesize
that the wide therapeutic window observed may be the result
of targeting this long-lasting pathogenic cascade within ischemic
endothelium (Figure 2). More recently, it has been proposed
that MBL contributes to cerebral damage by promoting local
microvascular thrombosis after ischemia in mice (de la Rosa
et al., 2014). In these studies, MBL-/- mice showed significantly
improved recovery of regional blood flow at 6 h and reduced
fibrinogen levels in the ischemic tissue 24 h after tMCAo when
compared to ischemic WT mice. Moreover, the administration
of argatroban, a thrombin inhibitor, significantly reduced neu-
rological deficits and ischemic volume in ischemic WT but not
in MBL-/- mice, suggesting that the deleterious effects of MBL
in the ischemic brain are partially mediated by thrombin acti-
vation. Additionally, MASP-1 and thrombin both share common
targets, including PARs, on endothelial cells (Megyeri et al., 2009),
suggestive of close interplay between LP and extrinsic pathway.
The existing data underscore the need for further elucidation
of the specific interaction between complement and coagulation
systems and its relevance to injury progression in acute brain
injury.
As previously stated, in addition to MBL, other activators
of LP like ficolins and CL-11 exist that may be relevant in
stroke. Available evidence indicate that among the currently-
identified LP initiators, ficolin-3 exhibits the highest blood con-
centration and activation capacity in humans (Hummelshoj et al.,
2008). In ischemic stroke patients, serum levels of ficolin-2 and
ficolin-3 have been shown to be significantly decreased com-
pared to non-ischemic controls, indicating that ficolins may be
consumed during the acute phases of ischemic pathology. Per-
haps more importantly, only ficolin-3 levels inversely correlate
with the stroke severity at admission (7–8 h) and with out-
come at 3–4 days (Füst et al., 2011), suggesting that ficolin-3
contributes to the pathogenic processes of cerebral ischemia. We
have recently demonstrated that the LP pathway is activated after
aneurysmal subarachnoid hemorrhage (SAH) in patients, and
that plasma concentrations of ficolin-3 reflect both the severity
of brain injury evaluated by clinical and structural parameters
and the extent of SAH-associated brain complications (Zanier
et al., 2014). In this rare stroke subtype characterized by the
bleeding of an intracranial aneurysm, brain ischemia is generally
believed to be the main determinant of unfavorable outcome
in the acute phase, occurring as result of initial intracranial
bleeding and/or at delayed stages as a consequence of vasospasm.
One explanation for the decrease of ficolin-3 and functional LP
activity is the consumption of this protein in the course of SAH-
related events. LP initiators can recognize and bind damage-
associated molecular patterns exposed by dying or reversibly
damaged cells through their carbohydrate recognition domain.
After stroke, injured endothelial cells may change their glyco-
sylation profile, thereby becoming the earliest suitable targets
for LP initiators. Overall, these data argue for a major role
of the LP, rather than the CP, in complement-mediated toxic
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effects after stroke and support the concept that the LP may
be selectively targeted to control injury progression in brain
ischemia.
The contribution of the AP following brain ischemia is, to
date, poorly understood. The major difficultly in assessing the
contribution of the AP to ischemic damage is that its main
activating protein C3, belongs not exclusively to the AP but also
to CP and LP. However, recent strategies have been developed
to obtain selective AP inhibition. Elvington et al. (2012) recently
employed both FB knock-out mice (FB-/-) and the adminis-
tration of CR2-fH, a specific inhibitor of the AP, in WT mice
and reported that FB-/- and CR2-fH-treated mice displayed sig-
nificant improvement in neurological scores, smaller ischemic
volume, reduced P-selectin expression, neutrophil infiltration and
microthrombi formation compared to WT or vehicle-treated
animals. Interestingly, FB-/- and CR2-fH-treated mice showed
less pronounced protective effects when compared to mice knock-
out for both C1q and MBL (C1q/MBL-/-) or WT mice treated
with CR2-Crry, which inhibits not only the alternative but the
whole activation pathways. In addition, FB-/- and CR2-fH-treated
mice, but not C1q/MBL-/- mice, showed increased brain C3d
deposition, supporting the hypothesis that the AP is not suf-
ficient per se to initiate post-ischemic complement activation
(Elvington et al., 2012). Thus overall the AP does not initiate
full complement activation but appears to contribute to the
propagation of cerebral injury via amplification of the other
cascades.
TRAUMATIC BRAIN INJURY
Evidence of complement system activation
The involvement of the complement system in TBI began to be
studied in the early 1990s. Although our current knowledge is
limited when compared to that of stroke, evidence has accu-
mulated from both clinical and experimental studies allowing
for the identification of critical complement-associated factors as
mediators of the pathophysiological sequelae of TBI.
A role for complement after TBI in patients has been sug-
gested by studies of cerebrospinal fluid (CSF; Kossmann et al.,
1997; Stahel et al., 2001) and cerebral contused tissue (Bellander
et al., 2001; Longhi et al., 2014). Following TBI, C3 and FB
levels were 20 and 4 times higher in CSF than those found in
controls, respectively (Kossmann et al., 1997). Moreover, C5b-9
levels were 1800-fold increased in TBI patients compared to non-
injured controls, suggestive of full activation of complement in
TBI (Stahel et al., 2001). Additionally, in contused brain tissue,
immunoreactivity for complement C3b, C3d and C5b-9 was
increased on neuronal cell surfaces (Bellander et al., 2001), while
no staining was detected in control tissue. These observations
suggest that complement activation occurs in brain cells following
TBI, possibly leading to an exacerbation of cerebral damage after
the initial (primary) injury. Extensive BBB damage in patients
following moderate to severe TBI may suggest that the major
source of complement factors may be the vascular compart-
ment, rather than intraparenchymal expression (Kossmann et al.,
1997).
Additional evidence for the role of complement in TBI comes
from several experimental animal models. The first study on
the effect of global complement inhibition in TBI employed
soluble CR1 (sCR1), a molecule that inhibits all complement
activation pathways by preventing the C3-convertase formation.
Rats pre-treated with sCR1 displayed a 41% reduction in neu-
trophil extravasation following TBI, suggesting that complete
complement system inhibition may attenuate vascular permeabil-
ity (Kaczorowski et al., 1995). Additionally, mice over-expressing
soluble Crry (sCryy, see Table 1), a C3 convertase inhibitor,
showed reduced BBB leakage and neurobehavioral deficits after
weight drop brain injury when compared to brain-injured WT
mice (Rancan et al., 2003). In this study, exogenous adminis-
tration of Crry-IgG (Crry fused with IgG1Fc for bioavailability
purpose) in brain-injured WT mice resulted in an attenuation of
neurological deficits at 4 and 24 h after TBI and a reduction of
neuronal loss in the hippocampus at 4 h compared with vehicle-
treatment (Rancan et al., 2003). Treatment with Crry-IgG not
only prevented C3 convertase activation, but also induced an
up-regulation of both complement-regulatory genes (C1-INH,
CD55 and CD59, see Table 1) and the anti-apoptotic Bcl-2 gene
(Leinhase et al., 2006). Although Crry may represent a promising
pharmacological treatment in the early phase after TBI, further
studies are needed to elucidate its protective mechanism of action
(Leinhase et al., 2006). Thus, similarly to what found in stroke
models, also in TBI C3 convertase may represent a therapeutical
target.
The specific role of C3 in TBI has been assessed in C3-/-
mice subjected to cortical controlled impact (CCI) brain injury.
Although brain-injured C3-/- mice did not differ from brain-
injured WT with respect to pre- or post-injury motor and
cognitive performance and brain lesion size after trauma, neu-
trophil recruitment was shown to decrease in these knock-
out mice by approximately 50% (You et al., 2007). Additional
effects were observed in C3-/- mice subjected to a traumatic
cryoinjury model, which mimics several aspects of the TBI
pathology, including BBB opening and brain edema. Using
this model, investigators reported decreased lesion volume and
vascular damage associated with reduced hemorrhage and neu-
trophil recruitment sustained by a diminished proinflamma-
tory gene expression (RANTES, Eotaxin, MCP-1 and migration
inhibitory factor, MIF) in brain-injured C3-/- mice (Sewell et al.,
2004). Although these contrasting data do not permit a clear
understanding of the exact role of C3 after TBI, the provoca-
tive observations, to date, argue for continued work in this
area.
The effect of TP over-activation has been studied in exper-
imental TBI using multiple approaches that have consistently
demonstrated a detrimental role for this pathway in TBI. In C5-/-
mice or in WT mice treated with C5aR antagonist, a significant
reduction of neutrophil extravasation after brain cryoinjury was
observed when compared to brain-injured control mice. Since
the degree of reduction was incomplete (only reaching 35%),
other complement chemoattractant molecules (e.g., C3a) may
play a more predominant role in regulating this process in
TBI (Sewell et al., 2004). Furthermore, after weight-drop TBI,
administration of a C5-binding protein complement inhibitor
(OmCI, administered up to 15 min after injury), which blocks
the generation of both C5a and C5b-9 (Fluiter et al., 2014),
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reduced neurological deficits, weight loss, C9 immunostain-
ing and microglia/macrophage activation compared with vehi-
cle treatment (Fluiter et al., 2014). OmCI treatment was also
associated with decreased neuronal apoptosis and axonal loss.
Since protective effects of OmCI treatment are known to be
associated with both C5a and C5b-9 inhibition, in order to bet-
ter understand the specific contribution of down-stream C5b-9,
its synthesis was subsequently prevented via the administration
of C6 mRNA antisense oligonucleotide. Similar neuroprotective
results were obtained to those observed after OmCI treatment
(Fluiter et al., 2014). These data highlight the potential role
of C5b-9 (vs C5/C5a) as a major mediator of complement-
mediated damage after TBI. However, to date, a selective C5
inhibitory strategy has not been evaluated experimentally using
a clinically relevant TBI model. The role of C5b-9 formation
has also been investigated using CD59-/- mice (see Table 1).
Following weight-drop brain injury, CD59 gene expression was
observed to be up-regulated in WT mice, suggestive of the acti-
vation of a neuronal protective mechanism against lysis. Brain-
injured CD59-/- mice showed increased neurobehavioral deficits
and neuronal cell death when compared to brain-injured WT
mice, suggesting that CD59 plays a direct role in protecting
the brain after TBI, possibly by inhibition of C5b-9 formation,
as previously described for stroke (Stahel et al., 2009). Over-
all, these studies underscore a role for full complement activa-
tion in the exacerbation of inflammatory processes leading to
neurobehavioral and anatomical damage after TBI and brain
ischemia.
Distinct roles of activation pathways
Beyond our understanding of the relevance of the end-stage
complement components in the pathobiological sequelae of TBI,
additional studies have begun to address the significance of
the activation of specific complement pathways. C4 is an inter-
mediate complement substrate belonging to both CP and LP
activation. Knock-out mice for this complement factor (C4-/-)
showed improved motor deficits and less post-injury damage
after CCI brain injury when compared to injured WT. Similarly,
administration of human C4 reversed the motor recovery in C4-/-
mice. These data, demonstrating that C4 impairs the recovery
of posttraumatic motor deficits and contributes to brain tissue
damage (You et al., 2007), suggest that CP and LP are both
involved in the pathogenesis of TBI.
In contused tissue from TBI patients, C1q immunoreactivity
was found on microglia/macrophage and astrocyte cell surfaces
close to the border zone of brain contusions (Bellander et al.,
2001). In mice, C1q gene expression increased both at 1 and 4 days
after CCI. However, C1q-/- mice did not show an amelioration
of neurobehavioral deficits and a reduction of tissue damage
after brain trauma compared to injured WT mice suggesting that
inhibition of C1q does not lead to neuroprotective effects in TBI
(You et al., 2007). These observations support those observed fol-
lowing cerebral ischemia and suggest that C1q does not represent
a major target for treatment of acute brain pathology following
CNS injury.
Similarly to what has been reported for stroke, C1-INH
(Table 1) has been revealed to possess neuroprotective properties
in TBI. Mice injected with C1-INH at 10 min or 1 h after CCI
brain injury showed a significant and long lasting improvement
of motor function over 4 weeks post-injury. Furthermore, mice
treated at 10 min showed improved cognitive outcome with a
concomitant decrease in lesion volume. These data demonstrate
that C1-INH may be protective via the modulation of early
mechanisms of secondary damage after TBI (Longhi et al., 2009).
Insight concerning the putative mechanisms of action of C1-
INH, obtained from experimental stroke studies (vide supra)
further supports a focus on the role of LP in TBI. We therefore
investigated the MBL presence in both human and experimental
TBI. In TBI patients, we demonstrated that MBL immunostaining
was present inside and around brain vessels in contused brain
tissue removed both early (<6 h) or late (4–5 d) following TBI.
Conversely, MBL staining was absent in control patients (Longhi
et al., 2014). Similarly, in mice subjected to CCI brain injury,
MBL was distributed inside and around brain vessels, visible up
to 1 week after CCI, possibly representing a long lasting event
after trauma (Longhi et al., 2014). The effect of MBL deletion
has been investigated in MBL-/- mice who showed increased
degenerating cells in hippocampus 6 h after mild CCI brain injury
with an exacerbation of neurobehavioral deficits 1 week post-
injury compared to brain-injured WT mice (Yager et al., 2008).
Conversely, when studied up to 5 weeks after severe CCI brain
injury, MBL-/- mice displayed better neurobehavioral outcome
beginning from the second up to the forth week after injury
when compared to WT. These behavioral improvements were
associated with reduced neuronal cell loss at 5 weeks (Longhi
et al., 2014). These findings suggest that MBL absence may lead
either to attenuation of mechanisms of secondary brain dam-
age or to the activation of reparative/regenerative processes that
occur at more chronic time points after injury (Longhi et al.,
2014). Similar to what has been described in models of stroke,
increasing evidence highlight the major contribution of the LP,
rather than the CP, in mediating secondary damage after TBI and
suggest that LP initiators are a viable therapeutic target for future
study to limit tissue damage and cell loss following acute CNS
injury.
Similar to studies in brain ischemia, few studies have been
performed regarding the role of the AP in TBI, to date. FB-/- mice
were reported to exhibit a robust decrease of C5a serum levels
at 4 h, 24 h and 7 d after weight-drop brain injury, suggesting
that AP activation contributes to overall complement activation.
In addition, FB-/- mice showed less neuronal death compared to
brain-injured WT at 7 days post-injury (Leinhase et al., 2006).
Additional studies have investigated the effect of anti-factor B
antibody administration which effectively reduces the activation
of the AP. Treatment with this compound conferred protection
against TBI-induced neuronal cell death, but did not improve
neurological deficits when compared to vehicle treatment. This
discrepancy was likely due to the lack of sensitivity of the neu-
rological tests employed to detect subtle changes in behavioral
performance (Leinhase et al., 2007). In summary, activation of the
AP in the setting of TBI appears to have a detrimental effect on
pathological and neurobehavioral outcome, although it remains
unclear whether this system plays a key role in triggering the full
complement activation.
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NEURODEGENERATIVE DISORDERS: THE EVIDENCE OF A
DELICATE BALANCE BETWEEN COMPLEMENT MEDIATED
PROTECTIVE AND TOXIC EFFECTS
Neurodegenerative disorders are defined as hereditary or sporadic
conditions caused by progressive loss of neuronal structures and
functions, until neuronal cell death. Many neurodegenerative
conditions, including Alzheimer’s disease (AD), Parkinson’s dis-
ease (PD) and amyotrophic lateral sclerosis (ALS), occur as a
result of this progressive neurodegenerative processes. Despite
they arise from different molecular aberrations, they show impor-
tant similarities in the pathogenic cellular mechanisms (e.g.,
protein misfolding, defective protein degradation pathways and
mitochondrial dysfunction) and in the immune response (com-
plement system and immune cell activation associated with
inflammation). Currently there are no drugs able to slow the
progression of these disorders.
Among the neurodegenerative disorders, AD is the most
common one. Thirty six million people worldwide were esti-
mated to be living with dementia in 2010, a number expected
to reach 115 million people by 2050 (Hugo and Ganguli,
2014). We will focus on the complex, versatile role of the
complement system in AD outlining emerging evidence that
show either beneficial or detrimental effects of this system
depending on the disease stage. Additionally we will dis-
cuss the limited data available on PD and ALS pathology.
A deeper knowledge on the role of the complement system
in neurodegenerative disorders may lead to new therapeutic
options.
ALZHEIMER’S DISEASE
Evidence of complement system activation
Since the early 1980s, the full range of classical and AP acti-
vation, involving all steps of the cascade through TP, has
been described to be associated with AD (Meraz-Ríos et al.,
2013).
In humans, multiple isoforms of complement factors have
been reported to be present in the CSF of AD patients. Differences
in patterns of complement factor expression between normal
controls and AD patients have also been reported at different
stages of the pathology, suggestive of a distinctive temporal pat-
tern of complement protein expression in relation to amyloid-β
(Aβ) plaque deposition and Aβ plaque maturation. CSF levels of
C1q, C3d and C4d have been found to increase during the early
stages of AD during Aβ formation, showing a positive correlation
with total plaque number from very mild to severe clinical cases
(Finehout et al., 2005; Wang et al., 2011; Daborg et al., 2012).
In post mortem studies comparing young, middle aged and old
cases, similar results have been obtained (Stoltzner et al., 2000),
documenting increased brain immunoreactivity for complement
proteins with age (Stoltzner et al., 2000; Veerhuis et al., 2003;
Fonseca et al., 2004a; Zanjani et al., 2005). The CP initiator C1q
has been found to be up-regulated up to 80-fold in areas of human
AD brains showing pathological neurodegeneration (Yasojima
et al., 1999), a relevant observation in view of the fact that C1q
is known to bind directly Aβ fibrils (fAβ) and neurofibrillary
tangles (Rogers et al., 1992; Jiang et al., 1994; Shen et al., 2001;
Webster et al., 2001; Veerhuis et al., 2003), underscoring the
need for a deeper understanding of the C1q specific role in AD
pathology.
Early vs. late disease stages
Manipulations of the complement system in experimental mod-
els have permitted the investigation of the role of the com-
plement components in AD. Recent in vitro and in vivo data
have highlighted a neuroprotective role of C1q. A direct positive
effect against Aβ fibrillar and oligomeric-induced neuronal death
in primary cortical neurons was demonstrated (Pisalyaput and
Tenner, 2008; Benoit et al., 2013). In vivo studies using AD
transgenic mouse models (one expressing the mutant form of
human amyloid precursor protein, hAPP and a second expressing
mutated Tau and/or presenilin 1) have been used to understand
the role of complement system in AD pathology. In these studies,
during the early stages of the disease, C1q induced a potent
cascade of neuroprotective gene expression via the activation of
the transcription factor cAMP response element-binding pro-
tein (CREB) and by increasing the expression of downstream
pro-survival effectors (low density lipoprotein receptor-related
protein 1B—LRP1B and G protein-coupled receptor 6—GPR6)
(Benoit et al., 2013). Conversely, at later stages of AD progression,
during Aβ accumulation, C1q-/- AD mice showed a significant
decreased microglial activation (50–60%) surrounding the Aβ
plaques accompanied by elevated expression of neuronal markers
with subsequent protective effect on neuronal integrity (Fonseca
et al., 2004b). Taken together, these data are suggestive of a
protective role for C1q in the early stages of AD, prior to Aβ
deposition, converting to a pathogenic role in association with
toxic events over time in the more chronic phases of the disease
(late stages).
Similar to C1q, increased C3 CSF levels in advanced AD
patients (Finehout et al., 2005; Wang et al., 2011; Daborg et al.,
2012) and C3 brain expression in aged AD transgenic mice (Wyss-
Coray et al., 2002; Zhou et al., 2008; Reichwald et al., 2009)
have been reported. The effects of experimental manipulation
of C3 on Aβ deposition, neuronal damage and activation of
inflammatory cells have been investigated by multiple approaches
at more chronic stages of AD pathology. Transgenic AD mice
(over-expressing hAPP and TGF-β) were found to have elevated
C3 brain levels associated with reduced Aβ accumulation (Wyss-
Coray et al., 2002). Inhibition of C3 convertase formation by
the transgenic expression of the sCrry gene, leading to loss of
opsonizing effect of C3b, was also shown to result in 2 to 3-fold
increase of Aβ accumulation and subsequent neurodegeneration
(Wyss-Coray et al., 2002). Subsequently, C3-/- transgenic AD
mice showed an age-associated increase in cerebral Aβ deposi-
tion and neuronal loss compared with C3-sufficient AD mice
(Maier et al., 2008). It is known that C3 products may act
as chemoattractant factors for microglial cells involved in the
clearance of Aβ protein deposits and C3 deficiency/inhibition
has been shown to consistently impair monocyte/macrophage
phagocytic capability, likely contributing to Aβ protein accumu-
lation (Maier et al., 2008). These studies demonstrate that the
absence/inhibition of the central complement component C3,
accelerates AD-like Aβ plaque pathology with aging once plaque
pathogenesis is underway and suggest that complement C3 may
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play an important role in maintaining tissue homeostasis (vide
infra). The mechanism(s) underlying the biological importance
of increased expression of C3 protein observed both in AD
humans and mice at delayed stages remains unclear and may
represent an attempt to protect the brain via C3 up-regulation
rather than a byproduct of neuronal damage (Maier et al.,
2008).
In contrast to the data available on C3, data concerning TP
products consistently suggest that they exert detrimental effects
during the pathological progression of AD (Yao et al., 1990). In
AD patients, an increase in the terminal components (C9 and
C5b-9) have been reported only in severe AD (Zanjani et al., 2005;
Loeffler et al., 2008). During plaque accumulation, the receptors
for C5a (C5aR) have been shown to increase and colocalize
with neurofibrillary tangles in human AD brains (Fonseca et al.,
2013). C5aR has been reported to be expressed in astrocytes
and microglia and to be up-regulated during neurodegenera-
tion (Woodruff et al., 2010). In vitro, the combination of Aβ-
protein and C5a activated monocytes/microglial cells induced
an increase in proinflammatory cytokines (O’Barr et al., 2001),
supporting the hypothesis that Aβ and C5a together can induce
a chronic microglia-mediated focal inflammatory response in
a synergistic manner. In vivo, an age- and disease-associated
up-regulation of C5aR on microglia in the proximity of Aβ
plaques has been reported in transgenic AD mice (Ager et al.,
2010). Inhibition of C5a using a C5aR antagonist, induced a
decrease in Aβ plaque burden and microglial activation with
a concomitant increase in cognitive performance in transgenic
AD mice (Fonseca et al., 2009). This effect does not appear
to be mediated by the modulation of C1q and/or C3, which
remain unaffected after treatment, but by the selective inhibition
of deleterious C5a–C5aR signaling (Ager et al., 2010). Thus,
the inhibition of the complement TP during AD progression
leads to a substantial improvement in behavioral and histopatho-
logical outcome in AD mice, suggesting that pharmacological
manipulation of this pathway may be a novel strategy to treat
neurodegeneration.
Little is known concerning the involvement of LP in
AD. Studies showing lower MBL levels in CSF of AD
patients when compared to controls (Lanzrein et al., 1998),
together with more recent evidence that MBL deficiency in
humans is associated with AD risk (Sjölander et al., 2013),
underscore the need for further studies to better charac-
terize the role of this pathway in AD pathogenesis and
progression.
Thus, AD represents an excellent paradigm to explore the
differential role of specific complement factors in relation
to time and degree of neuropathological injury. The avail-
able data indicate that the complement system plays a dual
role in AD pathogenesis and progression. Beneficial effects
of complement activation occur during the early stages of
AD (Fonseca et al., 2004b; Pisalyaput and Tenner, 2008;
Benoit et al., 2013), possibly contributing to Aβ plaques clear-
ance by microglia through complement-dependent opsonization
(mediated by C1q, C3b) (Alexander et al., 2008). Conversely,
during the more chronic phases of AD progression, comple-
ment activation appears to transition to a deleterious role,
contributing to neurotoxicity with subsequent exacerbation of
the inflammatory reaction at the site of injury (Alexander et al.,
2008).
PARKINSON’S DISEASE AND AMYOTROPHIC LATERAL SCLEROSIS
Evidence also exists for complement involvement in PD and
ALS. In PD patients, increased complement activation (through
formation of C5b-9), has been identified in Lewy bodies (LBs,
intraneuronal fibrillar aggregates containing a high concentration
of α-synuclein) and in oligodendroglia in the substantia nigra,
as well as in serum and CSF of patients with either sporadic or
familial PD (McGeer and McGeer, 2004; Goldknopf et al., 2006;
Wang et al., 2011; Depboylu et al., 2011a; More et al., 2013).
Similar to what has been observed in PD, increased complement
components in serum (C3c, C3d, FH), in CSF (C4d) (Tsuboi
and Yamada, 1994; Goldknopf et al., 2006), as well as in affected
postmortem spinal cord tissue (C1q/C2/C4/C3/MAC) have been
reported in ALS patients (Grewal et al., 1999; Sta et al., 2011).
In experimental rodent models of ALS pathology (one expressing
ALS-causing mutations in superoxide dismutase SOD1 and a
second engineered to be deficient in the low molecular weight
neurofilament- NFL subunit protein) similar findings have also
been reported in spinal cord (Lobsiger et al., 2007; Woodruff
et al., 2008; Humayun et al., 2009; Takeuchi et al., 2010; Heurich
et al., 2011; Lee et al., 2013) and along peripheral nerves (Chiu
et al., 2009). Increased expression of C1q reported in brain tissue
from humans and mouse models of both PD (Depboylu et al.,
2011a,b) and ALS (Lobsiger et al., 2007; Heurich et al., 2011;
Sta et al., 2011) highlights the potential involvement of C1q
in neurodegenerative processes via microglial-mediated synaptic
elimination. The lack of effect of C1q gene deletion on onset and
disease progression in either PD mice (Depboylu et al., 2011b),
or SOD1 mutant mice complicates our understanding of the role
of C1q in these conditions (Lobsiger et al., 2013) and the exact
role of CP in PD and ALS pathogenesis and progression remains
poorly understood.
No additional data are available concerning the possible role
of other complement proteins in PD. In ALS, however, the role
of C3 (Lobsiger et al., 2013) and C4 (Chiu et al., 2009) using gene
deletion techniques has been studied in SOD1 mutant mice show-
ing no major effect on outcome. Alternatively, recent evidence
suggests that the C5 downstream protein may be a key mediator
of complement-mediated neurotoxicity in ALS models. Studies
in transgenic SOD1 mutant rats and NFL knock-out mice have
reproducibly shown an up-regulation of the major proinflam-
matory C5aR during disease progression (Woodruff et al., 2008;
Humayun et al., 2009). Furthermore, chronic administration of
C5aR antagonist in transgenic SOD1 mutant rats was reported
to exert beneficial effects on neuronal survival during disease
progression (Woodruff et al., 2008). These results indicate that,
under stress, local complement signaling might therefore promote
damage and motor neuron death in ALS.
THE COMPLEMENT SYSTEM IN HOMEOSTASIS, PLASTICITY
AND REGENERATION
Growing evidence highlights that the versatile functions of
the complement system extend far beyond those of immune
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surveillance and the elimination/neutralization of pathogens and
altered host cells. Indeed, recent evidence point to an active
involvement of complement in lipid metabolism, angiogenesis,
tissue remodeling and maintenance in the CNS (Veerhuis et al.,
2003; Ricklin et al., 2010; Rutkowski et al., 2010; Stephan et al.,
2012).
SYNAPTIC REMODELING
Plasticity and remodeling of new synaptic circuits characterize the
early stages of brain development (Stephan et al., 2012). Molec-
ular and cellular mechanisms underlying synapse refinement
during development have been studied using the retinogeniculate
system. Early in development, axons from retinal ganglion cells
(RGCs) form transient functional synaptic connections with neu-
rons of dorsal lateral geniculate nucleus (dLGN). Subsequently,
during the first 2 weeks of post-natal development, the retino-
geniculate system circuit is subjected to precise sculpting through
the pruning of any overlapping or redundant transient connec-
tions and the strengthening of the remaining ones (Hooks and
Chen, 2006). The failure of this mechanism results in uncorrected
eye-segregation and visual deficits. During this period of synaptic
refinement, a close interaction/interplay amongst complement
proteins, immature astrocytes and neurons has been revealed to
occur. In the postnatal retinogeniculate system, TGF-β released
by immature astrocytes, induces in RGCs the up-regulation of
C1q which is transported from cell bodies along axons to the
dLGN, where it is released to bind transient synapses. C1q is
therefore believed to contribute to synapse elimination through
direct connection tagging (Eggleton et al., 2000) or through C3b
formation (Bialas and Stevens, 2013) that, in turn, opsonizes the
target synapses. The contribution of C1q and C3b to synaptoge-
nesis and synaptic remodeling is also supported by their punctate
colocalization with pre and postsynaptic markers during normal
retinogeniculate development (Stevens et al., 2007). However,
the mechanism that drives the opsonization process of synapses
destined to be pruned is not fully understood. Two different
mechanisms, both claiming a central role of complement opsonin
(C1q and C3b) and microglial interplay (Schafer et al., 2012),
have been suggested: (1) C1q and C3b, via an unknown selection
strategy, only tag the overlapping and weaker synapses, thereby
inducing their elimination by phagocytic microglia (Stevens et al.,
2007), or (2) C1q and C3b tag all synapses but the more active
or stronger ones are, in turn, able to express specific membrane-
bound complement inhibitors which confer selective protection
against microglial phagocytosis (Kim and Song, 2006; Kim et al.,
2008; Stephan et al., 2012). In addition, resident microglia are
not only involved in active phagocytosis of tagged synapses but
may participate to synaptic modeling through the secretion of
C1q. To this end, increased concentrations of C1q have been
shown to be present in microglia during the postnatal period that
coincides with the peak of synaptic refinement (Fiske and Brunjes,
2000). The involvement of C1q and C3 fragments in brain sculpt-
ing is likewise supported by studies in knock-out animals who
display an incorrect eye-specific segregation, due to overlapping
RGC projections and overabundant excitatory connectivity in
the cortex, resulting from defective synapse elimination (Stevens
et al., 2007; Chu et al., 2010; Stephan et al., 2012). However, the
phenotype of C1q-/- and C3-/- mice also shows residual synapse
refinement, suggesting that other molecules may participate in
this process, including both major histocompatibility complex I
(MHC-I) and neuronal pentraxins (Corriveau et al., 1998; Huh
et al., 2000; Bjartmar et al., 2006; Datwani et al., 2009). These
findings show that complement proteins are important in coop-
erating with other pathways to regulate normal synaptic circuit
development.
While complement activation and its interaction with
microglial cells appear necessary for brain wiring during the
postnatal period, recent evidence indicate that when this devel-
opmental program becomes aberrant in the immature brain or
is recapitulated during adulthood molecular cascades related to
neurodegenerative processes may be initiated (Stephan et al.,
2012). For example, during the postnatal period, the inappro-
priate activation of the complement cascade causes profound
synapse elimination that leads to neuropsychiatric diseases, such
as autism or schizophrenia (Patterson, 2011). Defects in pruning
have also been reported to be associated with the develop-
ment of epilepsy (Chu et al., 2010) or glaucoma (Howell et al.,
2011) where C1q and C3 are pathologically up-regulated and
cause destabilization of neuronal circuits (see Stephan et al.,
2012).
COMPLEMENT-MEDIATED EFFECTS ON CELLULAR WASTE REMOVAL
One of the main “housekeeping” functions of the complement
cascade involves the removal of apoptotic cells and the scavenging
of cellular debris and immune complexes. Senescent or defective
cells typically undergo apoptosis via a non-inflammatory cell
death. Normally, apoptotic cell bodies are rapidly removed to
avoid the unwanted over-activation of immunological processes,
since failure to clear or scavenge dead cells may induce an
exaggerated inflammatory reaction against other tissues (Savill
et al., 2002; Cole et al., 2006). Apoptosis induces membrane
phospholipid and ionic charge changes leading to deposition of
innate system effectors (Flierman and Daha, 2007). As for the
brain, in vitro studies have shown that C1q binds to neuronal
apoptotic cells and activates the CP with subsequent production
of opsonizing fragments (C3b and C4b), responsible for apoptotic
cell phagocytosis (Cole et al., 2006). Furthermore, biochemical
studies have demonstrated that C1q is able to bind IgM, serum
amyloid P component (SAP), CRP and pentraxin-3 (PTX3),
suggesting their involvement in C1q- mediated apoptotic cell
removal (Kishore et al., 2004). The relevance of C1q in the
physiological clearance of apoptotic cells has been studied in
C1q-/- mice who displayed an impaired elimination of immune
complexes and susceptibility to autoimmune disease (Mitchell
et al., 2002).
The overall role of phagocytosis is complex and depends on the
context. When occurring on the target cell dying by some means
such as apoptosis it is believed to be a beneficial activity, prevent-
ing the release of damaging and/or proinflammatory intracellular
components (referred to as “secondary phagocytosis”, Neher et al.,
2011, 2012). However, under certain conditions, such as acute
brain injury, complement overactivation may induce microglial
cells to phagocyte also viable neurons, thus executing their death
(referred to as “primary phagocytosis”) (Neher et al., 2011, 2012).
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After injury such phagocytic activity may result from exposure of
eat-me signals (C3b, C4b and C5b) on otherwise viable neurons
as a result of subtoxic and reversible insults, thus contributing to
injury amplification.
COMPLEMENT-MEDIATED EFFECTS ON MATURE BRAIN CELL SURVIVAL
AND ON NEUROGENESIS
In vitro studies have shown pro-survival effects of C1q in mature
brain cells, under normal conditions. Specifically, rat neuronal
cell cultures treated with C1q showed prolonged cell survival
associated with higher number of neuronal processes when com-
pared to untreated cells (Pisalyaput and Tenner, 2008). These
pro-survival effects of C1q may be due to an up-regulation
of cholesterol metabolism and cytoskeleton-related gene expres-
sion and to an increase of nerve growth factor (NGF) and
neurotrophin-3 protein levels (Benoit and Tenner, 2011). Indirect
evidence for a pro-survival action of C3a and C5a have also
been presented and C3a and C5a treatment of astrocytes and
microglial cell cultures has been shown to up-regulate NGF,
suggesting a common pro-survival pathway in the CNS under
normal conditions (Heese et al., 1998). Under neurodegenerative
conditions, a protective role of C1q and C3 in preserving tissue
homeostasis during AD progression has been reported (vide
supra).
Complement proteins have been shown to be involved in
migration and maturation of stem cells in the CNS under phys-
iological conditions. Neural stem and progenitor cells (NPCs)
have been reported to express C3aR and C5aR (Rahpeymai et al.,
2006). In vitro studies have demonstrated that treatment of NPCs
with C3a facilitates their migration and maturation without
affecting proliferation (Shinjyo et al., 2009). In addition, it has
been reported that mice treated with a C3aR antagonist display
reduced neurogenesis in different brain areas, including the sub-
ventricular zone (SVZ), hippocampal dentate gyrus and olfactory
bulb. Overall, these findings indicate that cellular signaling via
C3a positively regulates basal neurogenesis (Rahpeymai et al.,
2006).
Complement seems to be involved also in brain injury-induced
neurogenesis. After transient ischemia, C3-/- mice showed a
significant reduction (by 24%) in neurogenesis (doublecortin
positive cells) in the SVZ compared to ischemic WT mice
at 7 days after insult. Moreover, the reduction in neurogen-
esis was independent of either microglia activation or reac-
tive gliosis that remained unaffected in C3-/- compared to
WT mice (Rahpeymai et al., 2006). Further evidence suggest-
ing a contribution of C3a to CNS neurogenesis comes from
the literature concerning experimental neonatal brain ischemia.
Ischemic neonatal mice treated with C3a exhibited improved
memory function at 41 days and this effect was abolished in
C3aR-/- neonatal mice (Järlestedt et al., 2013). As discussed
previously, a large body of evidence has been generated demon-
strating the detrimental effects of several complement-activated
products after acute brain injury. While these findings sug-
gest a contribution of C3a to ischemia-induced neurogene-
sis, it should be emphasized that C3 is not a unique/major
neurogenic factor since consistent and residual neurogenesis
remains after C3 removal. Continued investigation addressing the
temporal role of the complement system in mediating neuro-
genesis in the injured brain is warranted to elucidate how the
delicate balance between complement-dependent neurotoxicity
and its potential neurogenic effects can be modulated to promote
neuroprotection.
CONCLUDING REMARKS
Far beyond the view of the complement as a supplementary
molecule needed for bacterial lysis, the available data show that
the complement cascade is involved in several aspects of brain
development, homeostasis, injury and regeneration. The ver-
satility of this cascade in participating in diverse processes in
the nervous system under both physiological and pathological
conditions appears to be dependent on a fine balance within an
intricate network of effectors, receptors and regulators. When the
critical factors involved with this system are finely regulated, they
participate in the maintenance of brain homeostasis. Conversely,
deregulation between activators and regulators leads to aberrant
complement activation with subsequent exacerbation of inflam-
mation and worsening of the damage induced by brain injury and
neurodegenerative diseases. Importantly, evidence that targeting
selective steps of this cascade leads to amelioration of brain injury
strongly support the concept of the complement system as an
important therapeutic target in brain injury and disease.
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